The functional integrity of the p53 signaling pathway was evaluated by treating CLL cells with the MDM2-p53 antagonist HDM201 for 24 h and assessing the protein expression of p53 transcriptional target genes. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.